{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:13:10Z","timestamp":1787850790219,"version":"build-2784847793"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite significant advances in the therapeutic management of Crohn\u2019s disease (CD), a subset of patients remains refractory to available treatments. Dual-targeted therapy (DTT), combining biologics or biologics with small molecules, has emerged as a promising approach. While evidence supporting DTT continues to grow, reports of patients treated with a combination of 3 biologic or targeted agents remain exceptionally rare.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Presentation<\/jats:title>\n                  <jats:p>We report the case of a 30-year-old male with a complex clinical course, initially diagnosed with ulcerative colitis and later reclassified as CD following ileal pouch-anal anastomosis, due to subsequent small bowel and perianal involvement. The patient also had concomitant ankylosing spondylitis. Despite multiple lines of therapy, including, anti-tumor necrosis factor agents, vedolizumab, ustekinumab, and upadacitinib, both CD and ankylosing spondylitis remained clinically active. In the absence of alternative therapeutic options and continued refusal of surgery, a triple combination of certolizumab pegol, ustekinumab, and vedolizumab was initiated and maintained over 10 months. While the treatment was well tolerated and ankylosing spondylitis remained in remission, no impact was observed on CD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This case highlights the challenges of managing refractory inflammatory bowel disease with overlapping immune-mediated conditions. Although the combination of biologics targeting distinct inflammatory pathways is conceptually appealing and supported by emerging data on DTT, the effectiveness of triple therapy remains uncertain in some patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Triple biologic therapy remains experimental and should be approached with caution, pending more robust evidence. Larger and translational studies are needed to better identify patients who may benefit, define optimal combinations, and clarify long-term safety of these combinations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf067","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T10:21:41Z","timestamp":1745058101000},"source":"Crossref","is-referenced-by-count":2,"title":["Triple biologic therapy for refractory Crohn\u2019s disease"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-7146","authenticated-orcid":false,"given":"Sophie","family":"Vieujean","sequence":"first","affiliation":[{"name":"Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Li\u00e8ge , Li\u00e8ge ,","place":["Belgium"]},{"name":"Department of Gastroenterology, INFINY Institute , CHRU Nancy, Vand\u0153uvre-l\u00e8s-Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, INFINY Institute , CHRU Nancy, Vand\u0153uvre-l\u00e8s-Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"2025060311002537600_CIT0001","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","author":"Vieujean","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025060311002537600_CIT0002","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311002537600_CIT0003","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ecco-jcc\/jjx143","article-title":"Vedolizumab in IBD-Lessons from real-world experience; a systematic review and pooled analysis","volume":"12","author":"Engel","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2025060311002537600_CIT0004","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/ecco-jcc\/jjad180","article-title":"Analysis of clinical trial screen failures in inflammatory bowel diseases [IBD]: real World Results from the International Organization for the study of IBD","volume":"18","author":"Vieujean","year":"2023","journal-title":"J Crohns Colitis."},{"key":"2025060311002537600_CIT0005","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/biom15020222","article-title":"Dual therapy in inflammatory bowel disease","volume":"15","author":"Altieri","year":"2025","journal-title":"Biomolecules."},{"key":"2025060311002537600_CIT0006","doi-asserted-by":"publisher","first-page":"S2573","DOI":"10.14309\/01.AJG.0001045208.51693.DE","article-title":"S3960 triple agent therapy as a novel approach to inflammatory bowel disease treatment","volume":"119","author":"Thomas","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"2025060311002537600_CIT0007","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3748\/wjg.v30.i15.2068","article-title":"Combination treatment of inflammatory bowel disease: present status and future perspectives","volume":"30","author":"Triantafillidis","year":"2024","journal-title":"World J Gastroenterol."},{"key":"2025060311002537600_CIT0008","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ueg2.12170","article-title":"Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: a European retrospective observational study","volume":"9","author":"Goessens","year":"2021","journal-title":"United European Gastroenterol J."},{"key":"2025060311002537600_CIT0009","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360."},{"key":"2025060311002537600_CIT0010","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/MCG.0000000000001583","article-title":"Dual targeted therapy for the management of inflammatory bowel disease","volume":"55","author":"Haider","year":"2021","journal-title":"J Clin Gastroenterol."},{"key":"2025060311002537600_CIT0011","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025060311002537600_CIT0012","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562848241307598","article-title":"Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China","volume":"18","author":"Jin","year":"2025","journal-title":"Therap Adv Gastroenterol."},{"key":"2025060311002537600_CIT0013","doi-asserted-by":"publisher","first-page":"otae080","DOI":"10.1093\/crocol\/otae080","article-title":"Dual biologic therapy induces remission in refractory Crohn\u2019s disease with Vedolizumab and Ustekinumab","volume":"7","author":"Hassan","year":"2025","journal-title":"Crohns Colitis 360."},{"key":"2025060311002537600_CIT0014","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","article-title":"Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn\u2019s Disease","volume":"69","author":"Miyatani","year":"2024","journal-title":"Dig Dis Sci."},{"key":"2025060311002537600_CIT0015","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn\u2019s disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf067\/62956581\/jjaf067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf067\/62956581\/jjaf067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf067\/62956581\/jjaf067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:01:38Z","timestamp":1748962898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf067\/8116446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf067","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,19]]},"article-number":"jjaf067"}}